Details of the Drug Combinations

General Information of This Drug (ID: DM6L4H2)

• Drug Name: Cobicistat (DM6L4H2)
• Synonyms: 1004316-88-4; Cobicistat (GS-9350); GS 9350; GS-9350; UNII-LW2E03M5PG; Cobicistat,GS-9350; CHEBI:72291; LW2E03M5PG; Tybost; thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate; 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl

Indication

Human immunodeficiency virus infection; ICD 11: 1C62; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

9 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cobicistat + Tenofovir alafenamide	DCHB3VE	Tenofovir alafenamide	HIV Infections	[2]
Cobicistat + Tenofovir alafenamide	DC9DNCT	Tenofovir alafenamide	HIV Infections	[2]
Cobicistat + Daclatasvir	DCHZZAH	Daclatasvir	Hepatitis C	[3]
Cobicistat + Voriconazole	DCVZ9OE	Voriconazole	Human Immunodeficiency Virus Type 1 (HIV-1) Infection	[4]
Cobicistat + Atazanavir	DC3OP08	Atazanavir	Human Immunodeficiency Virus Type 1 (HIV-1)	[5]
Cobicistat + Venetoclax	DC3CL07	Venetoclax	AML, Adult	[6]
Cobicistat + Darunavir	DCL4TNM	Darunavir	Coronavirus Disease 2019 (COVID-19)	[7]
Cobicistat + Darunavir	DCGBGII	Darunavir	AIDS-related Dementia Complex	[8]
Cobicistat + Olaparib	DC0PVC5	Olaparib	Cancer	[9]

2 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cobicistat + Emtricitabine	DCZW32N	Emtricitabine	Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection	[10]
Cobicistat + Darunavir	DC2HCN2	Darunavir	Human immunodeficiency virus infection	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535).
• [2] ClinicalTrials.gov (NCT04518228) Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
• [3] ClinicalTrials.gov (NCT02565888) A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
• [4] ClinicalTrials.gov (NCT05458102) Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
• [5] ClinicalTrials.gov (NCT01837719) Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
• [6] ClinicalTrials.gov (NCT06014489) A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
• [7] ClinicalTrials.gov (NCT04252274) Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
• [8] ClinicalTrials.gov (NCT02503462) Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
• [9] ClinicalTrials.gov (NCT05078671) Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
• [10] FDA Drug Development and Drug Interactions
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015